Jing Sun

TL;DR: CAR T cells bearing a functional chemokine receptor can overcome the inadequate tumor localization that limits conventional CAR targeting strategies and can significantly improve antitumor efficacy in vivo.

TL;DR: The results suggest that PD1 pathway antagonism may augment human CAR T-cell function, and will be an important tool for testing T cell–based strategies or systemic approaches to overcome this tumor-induced inhibition.

TL;DR: The existing literature which supports roles for inflammatory dynamics, immune function and alterations to cell signaling as consequences of variation in mtDNA-CN are reviewed, and it is proposed that future studies should focus on characterizing longitudinal, cell-type and cross-tissue profiles of mt DNA-CN.

TL;DR: Activation of tumor-associated macrophages by DMXAA is an efficient way to generate a CD8(+) T-cell-dependent antitumor immune response even in animals with relatively nonimmunogenic tumors.

TL;DR: The data from NSCLC models show that CCL2 blockade can inhibit the tumor growth of primary and metastatic disease, and the mechanisms include an alteration of the tumor macrophage phenotype and the activation of CTLs.